{"id":"https://openalex.org/W2498328577","doi":"https://doi.org/10.1158/1538-7445.am2016-ct133","title":"Abstract CT133: Association of programmed death-ligand 1 (PD-L1) and 2 (PD-L2) expression with nivolumab (NIVO) efficacy in advanced melanoma (MEL)","display_name":"Abstract CT133: Association of programmed death-ligand 1 (PD-L1) and 2 (PD-L2) expression with nivolumab (NIVO) efficacy in advanced melanoma (MEL)","publication_year":2016,"publication_date":"2016-07-15","ids":{"openalex":"https://openalex.org/W2498328577","doi":"https://doi.org/10.1158/1538-7445.am2016-ct133","mag":"2498328577"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2016-ct133","doi":"https://doi.org/10.1158/1538-7445.am2016-ct133","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2016-ct133","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058975989","display_name":"Scott J. Rodig","orcid":"https://orcid.org/0000-0003-1761-9769","observed_orcids":["https://orcid.org/0000-0003-1761-9769"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott J. Rodig","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005477709","display_name":"Evisa Gjini","orcid":"https://orcid.org/0000-0002-6951-9279","observed_orcids":["https://orcid.org/0000-0002-6951-9279","https://orcid.org/0009-0004-4495-6255"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Evisa Gjini","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075781740","display_name":"Kaushal D. Desai","orcid":"https://orcid.org/0000-0002-8941-2858","observed_orcids":["https://orcid.org/0000-0002-8941-2858"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kaushal Desai","raw_affiliation_strings":["2Bristol-Myers Squibb, Princeton, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Bristol-Myers Squibb, Princeton, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077194786","display_name":"Chelsea Jin","orcid":"https://orcid.org/0009-0000-4150-6671","observed_orcids":["https://orcid.org/0009-0000-4150-6671","https://orcid.org/0000-0003-1230-272X"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chelsea Jin","raw_affiliation_strings":["2Bristol-Myers Squibb, Princeton, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Bristol-Myers Squibb, Princeton, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110480128","display_name":"Christine E. Horak","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christine Horak","raw_affiliation_strings":["2Bristol-Myers Squibb, Princeton, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Bristol-Myers Squibb, Princeton, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055100979","display_name":"Mary Ruisi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary Ruisi","raw_affiliation_strings":["2Bristol-Myers Squibb, Princeton, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Bristol-Myers Squibb, Princeton, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047177507","display_name":"Jeffrey S. Weber","orcid":"https://orcid.org/0000-0002-4962-2957","observed_orcids":["https://orcid.org/0000-0002-4962-2957"]},"institutions":[{"id":"https://openalex.org/I4210086933","display_name":"NYU Langone Health","ror":"https://ror.org/005dvqh91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933"]},{"id":"https://openalex.org/I4390039310","display_name":"NYU Langone\u2019s Laura and Isaac Perlmutter Cancer Center","ror":"https://ror.org/00sa8g751","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933","https://openalex.org/I4390039310"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey Weber","raw_affiliation_strings":["3Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY","institution_ids":["https://openalex.org/I4210086933","https://openalex.org/I4390039310"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075310347","display_name":"Gordon James Freeman","orcid":"https://orcid.org/0000-0002-7210-5616","observed_orcids":["https://orcid.org/0000-0002-7210-5616"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gordon J. Freeman","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5084967339","display_name":"Frank Stephen Hodi","orcid":"https://orcid.org/0000-0001-6825-091X","observed_orcids":["https://orcid.org/0000-0001-6825-091X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F. Stephen Hodi","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"76","issue":"14_Supplement","first_page":"CT133","last_page":"CT133"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pd-l2","display_name":"PD-L2","score":1.0},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9919999837875366},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.9210000038146973},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.8259999752044678},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7289999723434448},{"id":"https://openalex.org/keywords/pd-1-pd-l1-blockade","display_name":"PD-1/PD-L1 blockade","score":0.6600000262260437},{"id":"https://openalex.org/keywords/tumor-markers","display_name":"tumor markers","score":0.5220000147819519},{"id":"https://openalex.org/keywords/treatment-response-prediction","display_name":"treatment response prediction","score":0.7260000109672546},{"id":"https://openalex.org/keywords/sequential-immunotherapy","display_name":"sequential immunotherapy","score":0.7300000190734863},{"id":"https://openalex.org/keywords/tumor-burden-reduction","display_name":"tumor burden reduction","score":0.6259999871253967},{"id":"https://openalex.org/keywords/response-rate","display_name":"response rate","score":0.8140000104904175}],"concepts":[{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.8713895082473755},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7821980118751526},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.7478084564208984},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6666661500930786},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.6370001435279846},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.633853018283844},{"id":"https://openalex.org/C204232928","wikidata":"https://www.wikidata.org/wiki/Q899285","display_name":"Immunohistochemistry","level":2,"score":0.5156006217002869},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5029951930046082},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4638751745223999},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4507361650466919},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.423429399728775},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.42198675870895386},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2500036656856537},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.19579613208770752},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.16756224632263184}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2016-ct133","doi":"https://doi.org/10.1158/1538-7445.am2016-ct133","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2016-ct133","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2587867179","https://openalex.org/W2345990767","https://openalex.org/W3120004960","https://openalex.org/W2561589030","https://openalex.org/W2181841765","https://openalex.org/W2741245320","https://openalex.org/W2442584486","https://openalex.org/W2490123200","https://openalex.org/W2286032567","https://openalex.org/W2739577140"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"NIVO":[2,64,73,86,106,282,293,300],"inhibits":[3],"the":[4,7,49,142,158,290,317,400,405],"interaction":[5],"of":[6,157,161,207,292,309,319,379,399,404],"PD-1":[8],"receptor":[9],"with":[10,26,31,85,141,203,209,217,248,257,296,306,388],"its":[11],"ligands,":[12,311],"PD-L1":[13,19,33,128,144,162,178,195,218,221,259],"and":[14,54,115,129,148,163,181,239,265,384],"PD-L2.":[15,45],"While":[16],"high":[17,249],"tumor":[18,139,236,337,344],"expression":[20,34,53,131,160,179,187,211,277,286,308,387],"results":[21],"in":[22,74,194,200,255,269,283,294,304,336,343,392],"greater":[23,234],"clinical":[24],"benefit":[25,36],"NIVO,":[27],"MEL":[28],"patients":[29],"(pts)":[30],"low-to-no":[32,258,297,307],"also":[35],"from":[37,56,192],"NIVO.":[38,320],"This":[39],"may":[40,278,287,315],"be":[41],"partially":[42,288],"attributed":[43],"to":[44,81,113,274,281,325],"Here,":[46],"we":[47],"analyzed":[48],"association":[50,262],"between":[51,263],"PD-L1/PD-L2":[52],"efficacy":[55,266,291,391],"a":[57,149,233],"phase":[58],"II":[59],"study":[60],"(CheckMate":[61],"064)":[62],"evaluating":[63],"followed":[65,71],"by":[66,72,134,167],"ipilimumab":[67],"(IPI)":[68],"vs":[69,220,225,250],"IPI":[70,94,104],"MEL.":[75,284],"Methods:":[76],"Pts":[77,109],"were":[78,110,132],"randomized":[79],"1:1":[80],"receive":[82],"sequential":[83],"treatment":[84,114],"(3":[87,95],"mg/kg":[88,96],"IV":[89,97],"Q2W":[90],"x":[91,99],"6)":[92],"then":[93,105],"Q3W":[98],"4)":[100],"(cohort":[101,107],"A)":[102],"or":[103,196],"B).":[108],"biopsied":[111],"prior":[112],"at":[116,125,243],"Wk":[117,126,244],"13;":[118],"pts":[119,176,184,208,216,247,256,295,305],"had":[120,177,185],"only":[121],"received":[122],"one":[123],"agent":[124],"13.":[127],"PD-L2":[130,151,164,186,197,210,252,264,276,285],"assessed":[133],"immunohistochemistry":[135],"on":[136],"formalin-fixed,":[137],"paraffin-embedded":[138],"samples":[140],"Dako":[143],"28-8":[145],"pharmDx":[146],"assay":[147,152],"novel":[150],"(antibody":[153],"clone":[154],"9E5).":[155],"Dichotomization":[156],"percent":[159],"was":[165,198,213,232,267],"optimized":[166],"ROC":[168],"analyses.":[169],"Results:":[170],"In":[171,228],"pre-treatment":[172],"samples,":[173],"32/97":[174],"(33%)":[175],"?5%":[180,219],"38/83":[182],"(46%)":[183],"?70%.":[188],"No":[189,261],"consistent":[190],"change":[191],"baseline":[193],"observed":[199,268],"either":[201],"cohort":[202,229,270],"treatment.":[204],"The":[205],"frequency":[206],"?70%":[212],"higher":[214,240],"among":[215,246],"<5%:":[222],"63%":[223],"(19/30)":[224],"36%":[226],"(17/47).":[227],"A,":[230],"there":[231],"mean":[235],"burden":[237],"reduction":[238],"response":[241,280],"rates":[242],"13":[245],"low":[251],"expression,":[253],"even":[254],"(Table).":[260],"B.":[271],"Conclusions:":[272],"Similar":[273],"PD-L1,":[275],"enrich":[279],"explain":[289,316],"PD-L1.":[298],"However,":[299],"is":[301,323],"still":[302],"active":[303],"both":[310],"suggesting":[312],"other":[313],"factors":[314],"activity":[318],"Further":[321],"analysis":[322],"required":[324],"delineate":[326],"these":[327],"factors.":[328],"ExpressionStatus,":[329],"%NCheckMateCheckMate064064Cohort":[330],"ACohort":[331],"BPD-L1PD-L2Tumor":[332],"response,":[333,340],"n/N":[334,341],"(%)Reduction":[335,342],"burden,":[338,345],"%Tumor":[339],"%\u22655\u226570197/13":[346],"(54)-26.62/6":[347],"(33)4.9\u22655<70112/7":[348],"(29)-13.30/4":[349],"(0)49.8<5\u226570174/10":[350],"(40)-28.40/7":[351],"(0)58.0<5<70304/18":[352],"(22)-2.80/12":[353],"(0)31.3":[354],"Citation":[355],"Format:":[356],"Scott":[357],"J.":[358,373],"Rodig,":[359],"Evisa":[360],"Gjini,":[361],"Kaushal":[362],"Desai,":[363],"Chelsea":[364],"Jin,":[365],"Christine":[366],"Horak,":[367],"Mary":[368],"Ruisi,":[369],"Jeffrey":[370],"Weber,":[371],"Gordon":[372],"Freeman,":[374],"F.":[375],"Stephen":[376],"Hodi.":[377],"Association":[378,407],"programmed":[380],"death-ligand":[381],"1":[382],"(PD-L1)":[383],"2":[385],"(PD-L2)":[386],"nivolumab":[389],"(NIVO)":[390],"advanced":[393],"melanoma":[394],"(MEL).":[395],"[abstract].":[396],"In:":[397],"Proceedings":[398],"107th":[401],"Annual":[402],"Meeting":[403],"American":[406],"for":[408],"Cancer":[409,420],"Research;":[410],"2016":[411],"Apr":[412],"16-20;":[413],"New":[414],"Orleans,":[415],"LA.":[416],"Philadelphia":[417],"(PA):":[418],"AACR;":[419],"Res":[421],"2016;76(14":[422],"Suppl):Abstract":[423],"nr":[424],"CT133.":[425]},"counts_by_year":[{"year":2016,"cited_by_count":2}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2016-08-23T00:00:00"}